Author: pr web

Bombardier launches the Global 8000 aircraft

Bombardier introduced the new Global 8000 aircraft at EBACE in Geneva on May 23, 2022

• Bombardier’s new Global 8000 aircraft stands alone as the world’s fastest and longest-range purpose-built business jet, innovatively crafted with the industry’s smoothest ride, healthiest cabin, and lowest cabin altitude
• With its innovative Smooth Flex Wing and super-efficient Passport engines, the Global 8000 jet features a top speed of Mach 0.94 – the fastest business jet in the skies
• The Global 8000 aircraft will be the only true four-zone cabin business jet to have a range of 8,000 nautical miles, unlocking even more city pairs than ever before
• Current Global 7500 operators will be able to retrofit their aircraft to experience the incredible performance enhancements on the Global 8000 aircraft

GENEVA, May 23, 2022 (GLOBE NEWSWIRE) — Bombardier today unveiled the newest member of its industry-leading business jet portfolio with the introduction of the Global 8000 aircraft, the world’s fastest and longest-range purpose-built business jet, innovatively crafted with the industry’s healthiest cabin for safety, comfort and performance beyond compromise.

With an industry-leading range of 8,000 nautical miles and an unbeatable top speed of Mach 0.94, the Global 8000 aircraft is the ultimate all-in-one business aircraft, offering customers a unique blend of outstanding performance married with the smoothest ride and an uncompromising passenger experience – the absolute leader in the long-range class.

“Today, Bombardier solidifies once more its position as the leader in business aviation with the newest member of the industry-leading Global family,” said Éric Martel, Bombardier’s President and Chief Executive Officer. “The Global 8000 aircraft leverages the outstanding attributes of the Global 7500 aircraft, providing our customers with a flagship aircraft of a new era. We remain unmatched, which for an innovation-focused team like us, is great.”

Some of the impressive performance capabilities of the new Global 8000 aircraft were witnessed as early as May 2021, following a demonstration flight with a Global 7500 flight test vehicle. The aircraft, accompanied by a NASA F/A-18 chase plane, repeatably achieved speeds in excess of Mach 1.015, a key step in enabling a maximum Mach operating speed (MMO) of M0.94 and becoming the fastest business jet in the world and the fastest in civil aviation since the Concorde. During the demonstration flight, the aircraft also became the first Transport Category airplane to fly supersonic with sustainable aviation fuel (SAF).

The discerning Global 8000 business jet also features the healthiest cabin in the industry, with the lowest cabin altitude in its class of 2,900 feet when flying at 41,000 ft. It is also equipped with Bombardier’s Pũr Air and advanced HEPA filter technology for the cleanest cabin air and the fastest fresh air replacement.

The Global 8000 aircraft is the only true four-zone cabin business jet to have a range of 8,000 nautical miles – and it more than delivers even when it comes to comfort. With its spacious four personalized suites ergonomically designed to maximize space and freedom of movement, the Global 8000 aircraft also incorporates the revolutionary features introduced on the Global 7500 aircraft that dramatically improve passenger comfort, including the Soleil circadian lighting system to help combat jet lag. Coupled with the innovative Nuage seat with the first-ever zero gravity position, passengers will arrive at their destinations revitalized and refreshed.

An exemplary commitment to detail is assured on the new Global 8000 aircraft, including an available Principal Suite with a full-size bed and a stand-up shower in the En-suite. Revolutionary cabin entertainment control and connectivity, the intuitive nice Touch CMS and OLED touch dial, Bombardier’s l’Opéra directional audio sound system and available 4K monitor, also ensures passengers will receive an unrivalled cabin experience.

In the cockpit, the Global 8000 aircraft features the renowned Bombardier Vision flight deck with its next generation fly-by-wire technology and blend of cutting-edge avionics with exceptional ergonomics and aesthetics for remarkable comfort and control.

Performance-wise, the new Global 8000 aircraft can efficiently transport customers to a wide variety of destinations both faster and farther than ever before. And with its exceptional class-leading range and short-field performance, even more exclusive city pairs are now achievable, including Dubai-Houston, Singapore-Los Angeles, London-Perth and many others.

Expected to enter service in 2025, the Global 8000 aircraft development is ongoing, and the program is progressing to plan. And for current Global 7500 operators, the incredible performance enhancements on the Global 8000 will be retrofittable when the aircraft enters into service in 2025.

The introduction of the new Global 8000 aircraft has been a carefully planned investment that further strengthens Bombardier’s impressive portfolio of industry-defining business jets. Development to date has been included in previously disclosed investment figures. All further development costs will be included in Bombardier’s capex, which remains in line with its 2025 objectives.

About Bombardier
Bombardier is a global leader in aviation, focused on designing, manufacturing, and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance, and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments, and private individuals. Bombardier aircraft are also trusted around the world in special-mission roles.

Headquartered in Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China, and an Australian facility opening in 2022.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier, Bombardier Vision, Global, Global 7500 and Global 8000 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries.

Visuals of the new Global 8000 aircraft are available here.

For information:
Matthew Nicholls
Bombardier
+1 514-243-8214
Matthew.Nicholls@aero.bombardier.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/77b1c210-6034-4eed-b9a1-09fcf7298160

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

The List recognizes and celebrates the generosity of changemakers from across the world who serve as an inspiration for future philanthropists.

SAN FRANCISCO and WASHINGTON, Aug. 12, 2021 (GLOBE NEWSWIRE) — Indiaspora, a nonprofit community of global Indian leaders from diverse backgrounds and professions, released today their list recognizing one hundred Indian and diaspora leaders who are making a difference through their giving.

“It is incredibly inspiring to see so many philanthropists from our community who have translated their success into social impact,” said Indiaspora Founder MR Rangaswami. “These leaders serve as an example of the importance of generosity and remind us of the many issues that need our attention.”

With guidance from nine jurors and drawing from multiple sources, including reputed studies, earlier verified lists, and publicly shared documents, Indiaspora’s 2021 Philanthropy Leaders List recognizes Indian and diaspora leaders across the globe for their philanthropic contributions and engagement.

“It was very gratifying to be a part of this effort, and I appreciated the careful consideration given to each honoree by those who were involved,” said Sara Kalim, Director of Development at Somerville College and one of the jurors. “As someone who works in the development space, I see firsthand how philanthropy can transform lives for the better. This list shines a light on the tremendous power of giving.”

With more than 32 million people of Indian origin globally, according to India’s Ministry of External Affairs, Indians are the largest diaspora population in the world. Indiaspora’s 2021 Philanthropy Leaders List includes philanthropists from India and from geographies with significant diaspora migration, including the United States, the United Kingdom, Canada, the United Arab Emirates, Singapore, and Australia. Several of these philanthropists stepped forward to give during the COVID-19 crisis.

“COVID-19 taught us that businesses, nonprofits, government, and philanthropy all play a critical role in lifting the communities they serve and operate in during times of crisis,” said Prem Watsa, Founder and CEO of Fairfax Financial Holdings and one of the honorees on the List. “Indiaspora’s Philanthropy Leaders List serves as a reminder to the diaspora to continue the important work of giving even once the crisis abates so our communities can meet future challenges.”

The List includes names from various industries including technology, entertainment, finance, and the law, among others, who are using their philanthropy to address issues such as access to healthcare, quality education, water and sanitation, arts and culture, food insecurity, and employability.

“I hope the diaspora will continue to give forward, and even more boldly,” said Rohini Nilekani, Founder-Chairperson of sustainable water and sanitation nonprofit Arghyam, who is also an honoree on the List. “It is both inspiring and critical to resolve many old and emerging societal challenges in India.”

Indiaspora’s 2021 Philanthropy Leaders List is one of several of the organization’s philanthropy-focused initiatives. Other initiatives include ChaloGive, an online giving campaign that raised more than $3.5M in 2021 to provide COVID relief in India, and the Philanthropy Summit, an annual event that brings together nonprofits, foundations, philanthropists, and others in the social impact space to share learnings regarding Indian and diaspora philanthropy.

“This is a transformative moment for philanthropy,” said Ashish Shah, Senior Director of Philanthropy and Community Engagement at Indiaspora. “The purpose of our philanthropy work is to galvanize the Indian diaspora to elevate its level of giving in the next decade, and Indiaspora’s 2021 Philanthropy Leaders List is an important step towards building a culture of philanthropy.”

For the list of honorees and additional resources, including additional quotes, information and news about the honorees, please visit the 2021 Indiaspora Philanthropy Leaders List website.

More on the Indiaspora Lists

The Indiaspora Lists (lists.indiaspora.org) highlight the advances of the Indian diaspora in areas such as government, business, and philanthropy.

Indiaspora’s inaugural Business Leaders List (July 2020), highlights the Indian diaspora who are leading the largest global companies and the Government Leaders List (February 2021) highlights over 200 government leaders of Indian heritage from 15 countries around the globe.

Indiaspora (www.indiaspora.org) is a nonprofit community of powerful global Indian leaders from diverse backgrounds and professions who are committed to inspiring the diaspora to be a force for positive impact by providing a platform to collaborate, engage, and catalyze social change.

Media contact:

Mansi Patel

Director of Communications, Indiaspora

mansi@indiaspora.org

cell: 772-486-0351

A Media Snippet accompanying this announcement is available by clicking on the image or link below: